Comparison of Anti-Xa and Dilute Russell Viper Venom Time Assays in Quantifying Drug Levels in Patients on Therapeutic Doses of Rivaroxaban

被引:42
作者
Gosselin, Robert C. [1 ]
Funk, Dorothy M. [2 ]
Taylor, J. Michael [2 ]
Francart, Suzanne J. [3 ]
Hawes, Emily M. [3 ,4 ]
Friedman, Kenneth D. [6 ]
Moll, Stephan [3 ,5 ]
机构
[1] Calif State Univ Sacramento, Davis Hlth Syst, Dept Pathol & Lab Med, Sacramento, CA 95819 USA
[2] Corp Amer Holdings, Colorado Coagulat, Englewood, CO 80112 USA
[3] Univ N Carolina, Dept Pharm, Chapel Hill, NC USA
[4] Univ N Carolina, Dept Family Med, Chapel Hill, NC 27514 USA
[5] Univ N Carolina, Hemophilia & Thrombosis Ctr, Chapel Hill, NC 27514 USA
[6] Blood Ctr Wisconsin, Hemostasis Reference Lab, Milwaukee, WI USA
关键词
PROTHROMBIN TIME; ORAL RIVAROXABAN; PLASMA; THROMBOPROPHYLAXIS; PERFORMANCE; HEPARIN; TESTS;
D O I
10.5858/arpa.2013-0750-OA
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context.-Rivaroxaban is a new oral anticoagulant that functions as a direct anti-Xa inhibitor. Although routine monitoring is not required, measurement of plasma concentrations may be necessary in certain clinical situations. Routine coagulation assays, such as the prothrombin time and, to a lesser degree, activated partial thromboplastin time, correlate with drug concentration, but because of reagent variability, these methods are not reliable for determining rivaroxaban anticoagulation. Objective.-To compare different methods and calibrators for measuring rivaroxaban, including the chromogenic anti-Xa assay, which, when calibrated with a rivaroxaban standard, may be more appropriate for determining anticoagulation. Design.-We compared measured rivaroxaban concentrations with the same anti-Xa kit but used different calibrators, with different anti-Xa kits but the same calibrators, with antithrombin-supplemented anti-Xa kit versus nonsupplemented kits, and with 2 methods based on rivaroxaban-calibrated, high-phospholipid, dilute Russell viper venom time. Regression and paired t test statistics were used to determine correlation and significant differences among methods and calibrator sources. Results.-Although there was strong correlation, statistically significant biases existed among methods that report rivaroxaban levels. A single-source calibrator did not alleviate those differences among methods. High-phospholipid Russell viper venom reagents correlated with rivaroxaban concentration but were not better than chromogenic anti-Xa methods. Conclusions.-Rivaroxaban-calibrated, anti-Xa measurements correlate well, but the clinical significance of the variation with rivaroxaban measurements is uncertain. The antithrombin-supplemented, anti-Xa method should be avoided for measuring rivaroxaban.
引用
收藏
页码:1680 / 1684
页数:5
相关论文
共 18 条
[1]   Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].
Barrett, Yu Chen ;
Wang, Zhaoqing ;
Frost, Charles ;
Shenker, Andrew .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271
[2]   Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].
Bauersachs, Rupert ;
Berkowitz, Scott D. ;
Brenner, Benjamin ;
Buller, Harry R. ;
Decousus, Herve ;
Gallus, Alex S. ;
Lensing, Anthonie W. ;
Misselwitz, Frank ;
Prins, Martin H. ;
Raskob, Gary E. ;
Segers, Annelise ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Bounameaux, Henri ;
Cohen, Alexander ;
Davidson, Bruce L. ;
Piovella, Franco ;
Schellong, Sebastian .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510
[3]   Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery Findings from the ORTHO-TEP registry [J].
Beyer-Westendorf, Jan ;
Luetzner, Joerg ;
Donath, Lars ;
Tittl, Luise ;
Knoth, Holger ;
Radke, Oliver C. ;
Kuhlisch, Eberhard ;
Stange, Thoralf ;
Hartmann, Albrecht ;
Guenther, Klaus-Peter ;
Weiss, Norbert ;
Werth, Sebastian .
THROMBOSIS AND HAEMOSTASIS, 2013, 109 (01) :154-163
[4]   Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism [J].
Buller, Harry R. ;
Prins, Martin H. ;
Lensing, Anthonie W. A. ;
Decousus, Herve ;
Jacobson, Barry F. ;
Minar, Erich ;
Chlumsky, Jaromir ;
Verhamme, Peter ;
Wells, Phil ;
Agnelli, Giancarlo ;
Cohen, Alexander ;
Berkowitz, Scott D. ;
Bounameaux, Henri ;
Davidson, Bruce L. ;
Misselwitz, Frank ;
Gallus, Alex S. ;
Raskob, Gary E. ;
Schellong, Sebastian ;
Segers, Annelise .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14) :1287-1297
[5]  
Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096
[6]   Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban [J].
Douxfils, Jonathan ;
Tamigniau, Anne ;
Chatelain, Bernard ;
Chatelain, Christian ;
Wallemacq, Pierre ;
Dogne, Jean-Michel ;
Mullier, Francois .
THROMBOSIS AND HAEMOSTASIS, 2013, 110 (04) :723-731
[7]   Assessment of the impact of rivaroxaban on coagulation assays: Laboratory recommendations for the monitoring of rivaroxaban and review of the literature [J].
Douxfils, Jonathan ;
Mullier, Francois ;
Loosen, Claire ;
Chatelain, Christian ;
Chatelain, Bernard ;
Dogne, Jean-Michel .
THROMBOSIS RESEARCH, 2012, 130 (06) :956-966
[8]   Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study [J].
Exner, Thomas ;
Ellwood, Lisa ;
Rubie, Jenny ;
Barancewicz, Aileen .
THROMBOSIS AND HAEMOSTASIS, 2013, 109 (04) :762-765
[9]   Performance of coagulation tests in patients on therapeutic doses of rivaroxaban A cross-sectional pharmacodynamic study based on peak and trough plasma levels [J].
Francart, Suzanne J. ;
Hawes, Emily M. ;
Deal, Allison M. ;
Adcock, Dorothy M. ;
Gosselin, Robert ;
Jeanneret, Cheryl ;
Friedman, Kenneth D. ;
Moll, Stephan .
THROMBOSIS AND HAEMOSTASIS, 2014, 111 (06) :1133-1140
[10]  
Harenberg J, 2012, J Thromb Haemost, V10, P1433, DOI 10.1111/j.1538-7836.2012.04784.x